Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 2
2010 1
2011 5
2012 7
2013 3
2014 3
2015 2
2016 4
2017 7
2018 5
2019 2
2020 6
2021 4
2022 8
2023 12
2024 15
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Intravenous Immune Globulin in Dermatomyositis.
Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis C, Schiopu E, Vencovský J, Beckmann I, Clodi E, Bugrova O, Dankó K, Ernste F, Goyal NA, Heuer M, Hudson M, Hussain YM, Karam C, Magnolo N, Nelson R, Pozur N, Prystupa L, Sárdy M, Valenzuela G, van der Kooi AJ, Vu T, Worm M, Levine T; ProDERM Trial Group. Aggarwal R, et al. Among authors: charles schoeman c. N Engl J Med. 2022 Oct 6;387(14):1264-1278. doi: 10.1056/NEJMoa2117912. N Engl J Med. 2022. PMID: 36198179 Clinical Trial.
Dr. Charles-Schoeman and E. Bananis Reply.
Charles-Schoeman C, Bananis E. Charles-Schoeman C, et al. J Rheumatol. 2018 Nov;45(11):1605. doi: 10.3899/jrheum.180489. Epub 2018 Nov 1. J Rheumatol. 2018. PMID: 30385698 No abstract available.
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Fleischmann R, et al. Among authors: charles schoeman c. Ann Rheum Dis. 2023 Sep;82(9):1130-1141. doi: 10.1136/ard-2023-223916. Epub 2023 Jun 12. Ann Rheum Dis. 2023. PMID: 37308218 Free PMC article. Clinical Trial.
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Charles-Schoeman C, et al. Ann Rheum Dis. 2023 Jan;82(1):119-129. doi: 10.1136/ard-2022-222259. Epub 2022 Sep 22. Ann Rheum Dis. 2023. PMID: 36137735 Free PMC article. Clinical Trial.
Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study.
Aggarwal R, Schessl J, Charles-Schoeman C, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Beckmann I, Clodi E, Levine T; ProDERM investigators. Aggarwal R, et al. Among authors: charles schoeman c. Arthritis Res Ther. 2024 Jan 17;26(1):27. doi: 10.1186/s13075-023-03232-2. Arthritis Res Ther. 2024. PMID: 38233885 Free PMC article. Clinical Trial.
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project.
Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, Dourado E, Sambataro G, Bauer-Ventura I, Bae SS, Lim D, Rivero-Gallegos D, Yamano Y, Selva-O'Callaghan A, Mammen AL, Scirè CA, Montecucco C, Oddis CV, Fiorentino D, Bonella F, Miller FW, Lundberg IE, Schmidt J, Rojas-Serrano J, Hudson M, Kuwana M, González-Gay MA, McHugh N, Corte TJ, Doyle TJ, Werth VP, Gupta L, Perez Roman DI, Bianchessi LM, Devarasetti PK, Shinjo SK, Luppi F, Cavazzana I, Moghadam-Kia S, Fornaro M, Volkmann ER, Piga M, Loarce-Martos J, De Luca G, Knitza J, Wolff-Cecchi V, Sebastiani M, Schiffenbauer A, Rider LG, Campanilho-Marques R, Marts L, Bravi E, Gunawardena H, Aggarwal R, Cavagna L; Classification Criteria for Anti‐Synthetase Syndrome Project participating investigators. Faghihi-Kashani S, et al. Arthritis Rheumatol. 2025 Apr;77(4):477-489. doi: 10.1002/art.43038. Epub 2024 Dec 17. Arthritis Rheumatol. 2025. PMID: 39467037 Free PMC article.
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.
Fleischmann R, Meerwein S, Charles-Schoeman C, Combe B, Hall S, Khan N, Carter KM, Camp HS, Rubbert-Roth A. Fleischmann R, et al. Among authors: charles schoeman c. RMD Open. 2024 Jul 25;10(3):e003918. doi: 10.1136/rmdopen-2023-003918. RMD Open. 2024. PMID: 39059811 Free PMC article. Clinical Trial.
87 results